Ep.4: Ozempic for the Brain, A New Era to Explain episode artwork

EPISODE · May 19, 2025 · 54 MIN

Ep.4: Ozempic for the Brain, A New Era to Explain

from Drug Dealin · host Drug Dealin Pod

Summary: In this episode, Shivu and Kenny delve into the evolving landscape of GLP-1 drugs, particularly focusing on the recent advancements in oral formulations and their potential applications beyond diabetes and obesity, including CNS diseases and addiction. They discuss the challenges of adherence, the mechanisms of action, and the economic implications of these therapies, while also highlighting the importance of early intervention in treatment. The conversation emphasizes the promising future of GLP-1s in various therapeutic areas and the ongoing research that will shape their role in healthcare.References:Shivu's recent substack post discussing GLP-1s for CNS disease: https://www.bigpharmasharma.com/p/what-2025-holds-for-glp-1s-in-brainGLP-1 Growth Graph: Zheng, Z., Zong, Y., Ma, Y. et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024).Contact us:Questions?: [email protected] us on X: ⁠https://x.com/DrugDealinPod⁠Follow Shivu : ⁠https://linktr.ee/shivusharma⁠Subscribe to Shivu's newsletter: https://www.bigpharmasharma.com/Follow Kenny: ⁠https://www.linkedin.com/in/kennylalwani/⁠Disclaimer: The views and opinions expressed in this podcast are for informational and educational purposes only. They are not intended as medical advice and should not be used as a substitute for professional medical judgment or guidance. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.Chapters00:00 Introduction to GLP-1s02:52 The Evolution of Oral GLP-1s06:26 Challenges in Patient Adherence10:34 Exploring CNS Impacts of GLP-1s14:44 Mechanisms of Action in CNS Diseases19:13 Potential in Addiction Treatment24:23 Future Directions and Research Opportunities30:20 Exploring the Mechanisms of New Medications35:16 Long-term Use and Dosing Challenges39:57 Promising Data in Addiction Treatment43:56 The Future of CNS and Metabolic Dysfunction Treatments50:44 The Path Forward in Drug Development54:50 Outro

Summary: In this episode, Shivu and Kenny delve into the evolving landscape of GLP-1 drugs, particularly focusing on the recent advancements in oral formulations and their potential applications beyond diabetes and obesity, including CNS diseases and addiction. They discuss the challenges of adherence, the mechanisms of action, and the economic implications of these therapies, while also highlighting the importance of early intervention in treatment. The conversation emphasizes the promising future of GLP-1s in various therapeutic areas and the ongoing research that will shape their role in healthcare.References:Shivu's recent substack post discussing GLP-1s for CNS disease: https://www.bigpharmasharma.com/p/what-2025-holds-for-glp-1s-in-brainGLP-1 Growth Graph: Zheng, Z., Zong, Y., Ma, Y. et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024).Contact us:Questions?: [email protected] us on X: ⁠https://x.com/DrugDealinPod⁠Follow Shivu : ⁠https://linktr.ee/shivusharma⁠Subscribe to Shivu's newsletter: https://www.bigpharmasharma.com/Follow Kenny: ⁠https://www.linkedin.com/in/kennylalwani/⁠Disclaimer: The views and opinions expressed in this podcast are for informational and educational purposes only. They are not intended as medical advice and should not be used as a substitute for professional medical judgment or guidance. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.Chapters00:00 Introduction to GLP-1s02:52 The Evolution of Oral GLP-1s06:26 Challenges in Patient Adherence10:34 Exploring CNS Impacts of GLP-1s14:44 Mechanisms of Action in CNS Diseases19:13 Potential in Addiction Treatment24:23 Future Directions and Research Opportunities30:20 Exploring the Mechanisms of New Medications35:16 Long-term Use and Dosing Challenges39:57 Promising Data in Addiction Treatment43:56 The Future of CNS and Metabolic Dysfunction Treatments50:44 The Path Forward in Drug Development54:50 Outro

NOW PLAYING

Ep.4: Ozempic for the Brain, A New Era to Explain

0:00 54:59

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Drug Dealin?

This episode is 54 minutes long.

When was this Drug Dealin episode published?

This episode was published on May 19, 2025.

What is this episode about?

Summary: In this episode, Shivu and Kenny delve into the evolving landscape of GLP-1 drugs, particularly focusing on the recent advancements in oral formulations and their potential applications beyond diabetes and obesity, including CNS diseases...

Can I download this Drug Dealin episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!